Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022
Report Scope:
This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.
The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.
The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.
Report Includes:
This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.
The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.
The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.
Report Includes:
- 28 data tables and 9 additional tables
- A comprehensive analysis of the ophthalmic device market by reviewing recent advances in diagnostic, surgical, and implantation devices that can be used to treat prevalent eye conditions.
- Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Breakdowns of the market by device, application, and region.
- Analysis of the recent advances in ophthalmic medical devices and their potential impact on the medical device industry.
- Evaluation of the market’s dynamics, specifically growth drivers, restraints, and opportunities.
- Company profiles of major players in the market, including AbbVie Inc., Bristol-Myers Squibb, Clovis Oncology, Inc., Eli Lilly and Company and Pfizer Inc.
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Market Context for Ovarian Cancer Therapies and Diagnostics
CHAPTER 3 OVERVIEW AND BIOLOGY
Overview
Biology
Metastasis
Risk Factors
Family History
Genetic Mutation
Lynch Syndrome
Peutz-Jeghers Syndrome
Age
Previous Conditions
Prevention
Birth Control
Childbearing Status
Removal of the Ovaries and Fallopian Tubes
Hysterectomy/Tubal Ligation
Symptoms
Gastrointestinal
Abdominal
Whole Body
Diagnosis
Overview
Current Screening Practices
Stages of Ovarian Cancer
Stage I
Stage II
Stage III
Stage IV
CHAPTER 4 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND
Market Definition and Overview
Market Drivers
Increase in Healthcare Expenditures
Continued Emphasis on R&D activities in Cancer and Treatment Technologies
Promised Potential of Alternative Therapies
Greater Understanding of the Genetic Base of lndividual Cancers
Increasing incidences of Ovarian Cancer Worldwide
Greater Use of Combination Therapies for Treatment
Increasing Cancer Prevalence Rates and Aging Population
Rising Awareness Among People with Cancer and Its Treatment
Market Restraints
Lack of Accurate Diagnosis of Ovarian Cancer
The Launch of Generic Drugs
Market Opportunities
Rising Female Population in the Asia-Pacific Region
Aging Demographics in Japan
Technological Advancements in the Drug Sector
Emergence of New Therapies for Disease Control
CHAPTER 5 MARKET BREAKDOWN BY DIAGNOSIS
Overview
Background
Diagnostic Tests
Pelvic Exam
Laboratory Tests
Recurrent Ovarian Epithelial Cancer
Market Forecast
New Developments
CHAPTER 6 OVARIAN CANCER TREATMENT
Treatment Strategies for Ovarian Cancer
Current Treatment Practices
Surgery
Chemotherapy
Intraperitoneal Chemotherapy
IV Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Palliative/Supportive Care
Recurrent Ovarian Cancer
Metastatic Ovarian Cancer
Sensitive Cancer Treatment
Resistant Cancer Treatment
Recurrent Ovarian Epithelial Cancer
Secondary Chemotherapy Drugs
Surveillance After Treatment
Novel Strategies for Prevention of Multidrug Resistance (MDR) in Cancer
CHAPTER 7 MARKET BREAKDOWN BY CANCER TYPE
Epithelial Ovarian Tumors
Germ Cell Tumors
Stromal Tumors
Primary Peritoneal Cancer
Stages of Ovarian Cancer
Stage
Stage
Stage
Stage
Prognosis
CHAPTER 8 MARKET BREAKDOWN BY REGION
Introduction
North America
U.S.
Canada
Europe
Acquisitions and Collaborations
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
India
China
Japan
Middle East & Africa
Drivers
Restraints
Latin America
Mexico
Drivers
Restraints
CHAPTER 9 PIPELINE ANALYSIS
Current Scenario
New Product Developments
VEGF Inhibitor
PARP Inhibitors
Promising Pipeline Molecules/Drugs in Development
Atezolizumab
Avelumab
Lurbinectedin
Veliparib
Trametinib
Fosbretabulin
Mirvetuximab Soravtansine
Most Promising Drug
ONX-0801
Recent Developments in the Ovarian Cancer Treatment
Gene Therapy Inhibited Chemoresistant Tumor
Synthetic Gene Circuit Development
Novel Combination Therapy
Birinapant
CancerSEEK
CHAPTER 10 PATENT ANALYSIS
Overview
Patent Expiration
CHAPTER 11 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS
Overview
Major Players and Market Share
Mergers and Acquisitions
AbbVie and Stemcentrx
Hikma Pharmaceuticals and EIMC United Pharmaceuticals
Roche and Ignyta
CHAPTER 12 COMPANY PROFILES
ABBVIE INC.
Business Overview
Products and Services
Imbruvica
Venclexta
Pipeline analysis
Acquisitions
Financials
ASTRA ZENECA
Business Overview
Products and Services
Tagrisso
Lynparza
Faslodex (Fulvestrant)
Zoladex
Ovarian Cancer Products
Developments and Strategies
Financials
BRISTOL-MYERS SQUIBB
Business Overview
Products and Services
Developments and Strategies
Financials
CELGENE CORP.
Business Overview
Products and Services
Financials
CLOVIS ONCOLOGY
Business Overview
Products and Services
ELI LILLY AND COMPANY
Business Overview
Products and Services
Gemzar
Developments and Strategies
Financials
GLAXOSMITHKLINE PLC
Business Overview
Developments and Strategies
Acquisition
Financials
HIKMA PHARMACEUTICALS PLC
Business Overview
Products and Services
Developments and Strategies
Acquisitions
Financials
JANSSEN PHARMACEUTICALS, INC.
Business Overview
Financials
MERCK & CO., INC.
Business Overview
Financials
MYRIAD GENETICS INC.
Business Overview
Products and Services
Financials
NOVARTIS AG
Business Overview
Products and Services
Financials
PFIZER INC.
Company Overview
Financials
QUEST DIAGNOSTICS INC.
Business Overview
Products and Services
Financials
ROCHE HOLDING AG
Business Overview
Products and Services
Acquisitions
Financials
TESARO, INC.
Business Overview
Products and Services
Immuno-Oncology Platform
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Market Context for Ovarian Cancer Therapies and Diagnostics
CHAPTER 3 OVERVIEW AND BIOLOGY
Overview
Biology
Metastasis
Risk Factors
Family History
Genetic Mutation
Lynch Syndrome
Peutz-Jeghers Syndrome
Age
Previous Conditions
Prevention
Birth Control
Childbearing Status
Removal of the Ovaries and Fallopian Tubes
Hysterectomy/Tubal Ligation
Symptoms
Gastrointestinal
Abdominal
Whole Body
Diagnosis
Overview
Current Screening Practices
Stages of Ovarian Cancer
Stage I
Stage II
Stage III
Stage IV
CHAPTER 4 MARKET DYNAMICS AND TECHNOLOGY BACKGROUND
Market Definition and Overview
Market Drivers
Increase in Healthcare Expenditures
Continued Emphasis on R&D activities in Cancer and Treatment Technologies
Promised Potential of Alternative Therapies
Greater Understanding of the Genetic Base of lndividual Cancers
Increasing incidences of Ovarian Cancer Worldwide
Greater Use of Combination Therapies for Treatment
Increasing Cancer Prevalence Rates and Aging Population
Rising Awareness Among People with Cancer and Its Treatment
Market Restraints
Lack of Accurate Diagnosis of Ovarian Cancer
The Launch of Generic Drugs
Market Opportunities
Rising Female Population in the Asia-Pacific Region
Aging Demographics in Japan
Technological Advancements in the Drug Sector
Emergence of New Therapies for Disease Control
CHAPTER 5 MARKET BREAKDOWN BY DIAGNOSIS
Overview
Background
Diagnostic Tests
Pelvic Exam
Laboratory Tests
Recurrent Ovarian Epithelial Cancer
Market Forecast
New Developments
CHAPTER 6 OVARIAN CANCER TREATMENT
Treatment Strategies for Ovarian Cancer
Current Treatment Practices
Surgery
Chemotherapy
Intraperitoneal Chemotherapy
IV Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Palliative/Supportive Care
Recurrent Ovarian Cancer
Metastatic Ovarian Cancer
Sensitive Cancer Treatment
Resistant Cancer Treatment
Recurrent Ovarian Epithelial Cancer
Secondary Chemotherapy Drugs
Surveillance After Treatment
Novel Strategies for Prevention of Multidrug Resistance (MDR) in Cancer
CHAPTER 7 MARKET BREAKDOWN BY CANCER TYPE
Epithelial Ovarian Tumors
Germ Cell Tumors
Stromal Tumors
Primary Peritoneal Cancer
Stages of Ovarian Cancer
Stage
Stage
Stage
Stage
Prognosis
CHAPTER 8 MARKET BREAKDOWN BY REGION
Introduction
North America
U.S.
Canada
Europe
Acquisitions and Collaborations
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
India
China
Japan
Middle East & Africa
Drivers
Restraints
Latin America
Mexico
Drivers
Restraints
CHAPTER 9 PIPELINE ANALYSIS
Current Scenario
New Product Developments
VEGF Inhibitor
PARP Inhibitors
Promising Pipeline Molecules/Drugs in Development
Atezolizumab
Avelumab
Lurbinectedin
Veliparib
Trametinib
Fosbretabulin
Mirvetuximab Soravtansine
Most Promising Drug
ONX-0801
Recent Developments in the Ovarian Cancer Treatment
Gene Therapy Inhibited Chemoresistant Tumor
Synthetic Gene Circuit Development
Novel Combination Therapy
Birinapant
CancerSEEK
CHAPTER 10 PATENT ANALYSIS
Overview
Patent Expiration
CHAPTER 11 COMPETITIVE LANDSCAPE AND KEY DEVELOPMENTS
Overview
Major Players and Market Share
Mergers and Acquisitions
AbbVie and Stemcentrx
Hikma Pharmaceuticals and EIMC United Pharmaceuticals
Roche and Ignyta
CHAPTER 12 COMPANY PROFILES
ABBVIE INC.
Business Overview
Products and Services
Imbruvica
Venclexta
Pipeline analysis
Acquisitions
Financials
ASTRA ZENECA
Business Overview
Products and Services
Tagrisso
Lynparza
Faslodex (Fulvestrant)
Zoladex
Ovarian Cancer Products
Developments and Strategies
Financials
BRISTOL-MYERS SQUIBB
Business Overview
Products and Services
Developments and Strategies
Financials
CELGENE CORP.
Business Overview
Products and Services
Financials
CLOVIS ONCOLOGY
Business Overview
Products and Services
ELI LILLY AND COMPANY
Business Overview
Products and Services
Gemzar
Developments and Strategies
Financials
GLAXOSMITHKLINE PLC
Business Overview
Developments and Strategies
Acquisition
Financials
HIKMA PHARMACEUTICALS PLC
Business Overview
Products and Services
Developments and Strategies
Acquisitions
Financials
JANSSEN PHARMACEUTICALS, INC.
Business Overview
Financials
MERCK & CO., INC.
Business Overview
Financials
MYRIAD GENETICS INC.
Business Overview
Products and Services
Financials
NOVARTIS AG
Business Overview
Products and Services
Financials
PFIZER INC.
Company Overview
Financials
QUEST DIAGNOSTICS INC.
Business Overview
Products and Services
Financials
ROCHE HOLDING AG
Business Overview
Products and Services
Acquisitions
Financials
TESARO, INC.
Business Overview
Products and Services
Immuno-Oncology Platform
LIST OF TABLES
Summary Table A: Global Ovarian Cancer Therapeutic Market, by Cancer Type, Through 2022
Summary Table B: Global Ovarian Cancer Therapeutic Market, by Region, Through 2022
Table 1: Imaging Tests and Functionality
Table 2: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Cancer, by Category, Through 2022
Table 3: Global Ovarian Cancer Therapeutics Market, by Cancer Type, Through 2022
Table 4: Stage 1 and Substages of Ovarian Cancer
Table 5: Stage 2 and Substages of Ovarian Cancer
Table 6: Stage 3 and Substages of Ovarian Cancer
Table 7: Stage 4 and Substages of Ovarian Cancer
Table 8: Global Ovarian Cancer Therapeutics Market, by Region, Through 2022
Table 9: North America Ovarian Cancer Therapeutics Market, Through 2022
Table 10: Europe Ovarian Cancer Therapeutics Market, Through 2022
Table 11: Asia-Pacific Ovarian Cancer Therapeutics Market, Through 2022
Table 12: Middle East and Africa Ovarian Cancer Therapeutics Market, Through 2022
Table 13: Latin America Ovarian Cancer Therapeutics Market, Through 2022
Table 14: PARP Inhibitors
Table 15: Pipeline Drugs Summary, by Phase
Table 16: Global Sales at Risk from Patent Expiration, 2016-2022
Table 17: Drugs Scheduled to Lose Patent Protection, 2018
Table 18: Drugs Scheduled to Lose Patent Protection, 2019
Table 19: Oncology Segment Revenue of Major Players, 2016
Table 20: AbbVie Inc.'s Revenue, 2015-2016
Table 21: AstraZeneca's Revenue, 2015-2016
Table 22: Lynparza's Revenue, 2015-2016
Table 23: Bristol-Myers Squibb's Revenue, 2015-2016
Table 24: Celgene Corp.'s Revenue, 2015–2016
Table 25: Eli Lilly and Company's Revenue, 2015-2016
Table 26: GlaxoSmithKline's Revenue, 2015-2016
Table 27: Hikma Pharmaceutical's Revenue, 2015-2016
Table 28: J&J's Revenue, 2015-2016
Table 29: Merck & Co., Inc.'s Net Revenue, 2014-2016
Table 30: Myriad Genetics, Inc.'s Revenue, 2015-2016
Table 31: Novartis AG's Revenue, 2015-2016
Table 32: Pfizer, Inc.'s Net Revenue, 2014-2016
Table 33: Quest Diagnostics, Inc.'s Revenue, 2015-2016
Table 34: Roche Holding's Revenue, 2015-2016
Table 35: Avastin's Drug Revenue, 2015-2016
Summary Table A: Global Ovarian Cancer Therapeutic Market, by Cancer Type, Through 2022
Summary Table B: Global Ovarian Cancer Therapeutic Market, by Region, Through 2022
Table 1: Imaging Tests and Functionality
Table 2: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Cancer, by Category, Through 2022
Table 3: Global Ovarian Cancer Therapeutics Market, by Cancer Type, Through 2022
Table 4: Stage 1 and Substages of Ovarian Cancer
Table 5: Stage 2 and Substages of Ovarian Cancer
Table 6: Stage 3 and Substages of Ovarian Cancer
Table 7: Stage 4 and Substages of Ovarian Cancer
Table 8: Global Ovarian Cancer Therapeutics Market, by Region, Through 2022
Table 9: North America Ovarian Cancer Therapeutics Market, Through 2022
Table 10: Europe Ovarian Cancer Therapeutics Market, Through 2022
Table 11: Asia-Pacific Ovarian Cancer Therapeutics Market, Through 2022
Table 12: Middle East and Africa Ovarian Cancer Therapeutics Market, Through 2022
Table 13: Latin America Ovarian Cancer Therapeutics Market, Through 2022
Table 14: PARP Inhibitors
Table 15: Pipeline Drugs Summary, by Phase
Table 16: Global Sales at Risk from Patent Expiration, 2016-2022
Table 17: Drugs Scheduled to Lose Patent Protection, 2018
Table 18: Drugs Scheduled to Lose Patent Protection, 2019
Table 19: Oncology Segment Revenue of Major Players, 2016
Table 20: AbbVie Inc.'s Revenue, 2015-2016
Table 21: AstraZeneca's Revenue, 2015-2016
Table 22: Lynparza's Revenue, 2015-2016
Table 23: Bristol-Myers Squibb's Revenue, 2015-2016
Table 24: Celgene Corp.'s Revenue, 2015–2016
Table 25: Eli Lilly and Company's Revenue, 2015-2016
Table 26: GlaxoSmithKline's Revenue, 2015-2016
Table 27: Hikma Pharmaceutical's Revenue, 2015-2016
Table 28: J&J's Revenue, 2015-2016
Table 29: Merck & Co., Inc.'s Net Revenue, 2014-2016
Table 30: Myriad Genetics, Inc.'s Revenue, 2015-2016
Table 31: Novartis AG's Revenue, 2015-2016
Table 32: Pfizer, Inc.'s Net Revenue, 2014-2016
Table 33: Quest Diagnostics, Inc.'s Revenue, 2015-2016
Table 34: Roche Holding's Revenue, 2015-2016
Table 35: Avastin's Drug Revenue, 2015-2016
LIST OF FIGURES
Summary Figure A: Global Ovarian Cancer Therapeutic Market, by Cancer Type, 2016-2022
Summary Figure B: Global Ovarian Cancer Therapeutic Market, by Region, 2016-2022
Figure 1: Woman's Reproductive System
Figure 2: Ovarian Cancer Symptoms
Figure 3: Pelvic Examination
Figure 4: Transvaginal Ultrasound (TVUS)
Figure 5: Pelvic Examination
Figure 6: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Cancer, 2016-2022
Figure 7: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Ovarian Cancer, 2016-2022
Figure 8: Epithelial Cancer Therapy Market, 2016-2022
Figure 9: Germ Cell Cancer Therapy Market, 2016-2022
Figure 10: Stromal Cancer Therapy Market, 2016-2022
Figure 11: Primary Peritoneal Cancer Therapy Market, 2016-2022
Figure 12: Stage 1 and Substages of Ovarian Cancer
Figure 13: Stage 2 and Substages of Ovarian Cancer
Figure 14: Stage 3 and Substages of Ovarian Cancer
Figure 15: Stage 4 and Substages of Ovarian Cancer
Figure 16: U.S. Ovarian Cancer Therapeutics Market, 2016-2022
Figure 17: Canada Ovarian Cancer Therapy Market, 2016-2022
Figure 18: Germany Ovarian Cancer Therapy Market, 2016-2022
Figure 19: U.K. Ovarian Cancer Therapy Market, 2016-2022
Figure 20: France Ovarian Cancer Therapy Market, 2016-2022
Figure 21: Italy Ovarian Cancer Therapy Market, 2016-2022
Figure 22: Spain Ovarian Cancer Therapy Market, 2016-2022
Figure 23: RoE Ovarian Cancer Therapy Market, 2016-2022
Figure 24: India Ovarian Cancer Therapy Market, 2016-2022
Figure 25: China Ovarian Cancer Therapy Market, 2016-2022
Figure 26: Japan Ovarian Cancer Therapy Market, 2016-2022
Figure 27: Middle East and Africa Ovarian Cancer Therapy Market, 2016-2022
Figure 28: Mexico Ovarian Cancer Therapy Market, 2016-2022
Figure 29: Lurbinectedin Chemical Structure
Figure 30: Velaparib Chemical Structure
Figure 31: Trametinib (Mekinist) Chemical Structure
Figure 32: Fosbretabulin Chemical Structure
Figure 33: Mirvetuximab Soravtansine Chemical Structure
Figure 34: ONX-0801 Chemical Structure
Figure 35: CancerSEEK Test
Figure 36: Global Sales at Risk from Patent Expiration, 2016-2022
Figure 37: Global Market Share of Major Players in OC Therapy Industry, 2016
Figure 38: Merck & Co., Inc.'s Revenue Share, by Business Segment, 2016
Figure 39: Merck & Co., Inc. Revenue Share, by Region, 2016
Figure 40: Pfizer, Inc.'s Revenue Share, by Region, 2016
Figure 41: Pfizer, Inc.'s Revenue Share, by Business Segment, 2016
Summary Figure A: Global Ovarian Cancer Therapeutic Market, by Cancer Type, 2016-2022
Summary Figure B: Global Ovarian Cancer Therapeutic Market, by Region, 2016-2022
Figure 1: Woman's Reproductive System
Figure 2: Ovarian Cancer Symptoms
Figure 3: Pelvic Examination
Figure 4: Transvaginal Ultrasound (TVUS)
Figure 5: Pelvic Examination
Figure 6: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Cancer, 2016-2022
Figure 7: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Ovarian Cancer, 2016-2022
Figure 8: Epithelial Cancer Therapy Market, 2016-2022
Figure 9: Germ Cell Cancer Therapy Market, 2016-2022
Figure 10: Stromal Cancer Therapy Market, 2016-2022
Figure 11: Primary Peritoneal Cancer Therapy Market, 2016-2022
Figure 12: Stage 1 and Substages of Ovarian Cancer
Figure 13: Stage 2 and Substages of Ovarian Cancer
Figure 14: Stage 3 and Substages of Ovarian Cancer
Figure 15: Stage 4 and Substages of Ovarian Cancer
Figure 16: U.S. Ovarian Cancer Therapeutics Market, 2016-2022
Figure 17: Canada Ovarian Cancer Therapy Market, 2016-2022
Figure 18: Germany Ovarian Cancer Therapy Market, 2016-2022
Figure 19: U.K. Ovarian Cancer Therapy Market, 2016-2022
Figure 20: France Ovarian Cancer Therapy Market, 2016-2022
Figure 21: Italy Ovarian Cancer Therapy Market, 2016-2022
Figure 22: Spain Ovarian Cancer Therapy Market, 2016-2022
Figure 23: RoE Ovarian Cancer Therapy Market, 2016-2022
Figure 24: India Ovarian Cancer Therapy Market, 2016-2022
Figure 25: China Ovarian Cancer Therapy Market, 2016-2022
Figure 26: Japan Ovarian Cancer Therapy Market, 2016-2022
Figure 27: Middle East and Africa Ovarian Cancer Therapy Market, 2016-2022
Figure 28: Mexico Ovarian Cancer Therapy Market, 2016-2022
Figure 29: Lurbinectedin Chemical Structure
Figure 30: Velaparib Chemical Structure
Figure 31: Trametinib (Mekinist) Chemical Structure
Figure 32: Fosbretabulin Chemical Structure
Figure 33: Mirvetuximab Soravtansine Chemical Structure
Figure 34: ONX-0801 Chemical Structure
Figure 35: CancerSEEK Test
Figure 36: Global Sales at Risk from Patent Expiration, 2016-2022
Figure 37: Global Market Share of Major Players in OC Therapy Industry, 2016
Figure 38: Merck & Co., Inc.'s Revenue Share, by Business Segment, 2016
Figure 39: Merck & Co., Inc. Revenue Share, by Region, 2016
Figure 40: Pfizer, Inc.'s Revenue Share, by Region, 2016
Figure 41: Pfizer, Inc.'s Revenue Share, by Business Segment, 2016
